Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)
Open Access
- 20 June 2014
- journal article
- editorial
- Published by Elsevier in Annals of Oncology
- Vol. 25 (9) , 1673-1678
Abstract
In its broadest sense, ‘personalised medicine’ is the tailoring of medical treatment to the characteristics of an individual patient and moves beyond the current approach of stratifying patients into treatment groups based on phenotypic biomarkers. Nowhere in medicine has the impact of personalised medicine been greater than in oncology. For scientists and oncologists, the term ‘personalised medicine’ is often used interchangeably with terms such as ‘genomic medicine’, ‘precision medicine’ and ‘precision oncology’. These terms are used to describe the use of an individual patient's molecular information (including genomics and proteomics) to inform diagnosis, prognosis, treatment and prevention of cancer for that patient. As the transition from stratified cancer medicine to truly personalised cancer medicine intensifies, it is this definition that the ESMO Personalised Medicine Task Force prefers to use when describing personalised cancer medicine. But irrespective of the term used, the direction of travel is clear—precision diagnosis and treatment of cancer at the molecular level—and this change in paradigm has profound implications, from preclinical definition of mechanism of action to the development of molecular taxonomies of cancer, and from genome diagnostics to trial design.Keywords
Funding Information
- ESMO
This publication has 33 references indexed in Scilit:
- Reflections on Market Access for Personalized Medicine: Recommendations for EuropeValue in Health, 2013
- Journeys into the genome of cancer cellsEMBO Molecular Medicine, 2013
- Knowledge engineering for health: A new discipline required to bridge the “ICT gap” between research and healthcareHuman Mutation, 2012
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- International network of cancer genome projectsNature, 2010
- Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapyNature Genetics, 2009
- KRAS Mutation Testing in Colorectal CancerAdvances in Anatomic Pathology, 2009
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001